Login / Signup

Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions.

Harshabad SinghYvonne Y LiLiam F SpurrAtul B ShinagareRitika AbhyankarEmma ReillyLauren K BraisAnwesha NagMatthew D DucarAaron R ThornerGeoffrey I ShapiroRachel B KellerCheta SilettiJeffrey W ClarkAnna F FaragoJessica J LinGeorge D DemetriRahul GujrathiMatthew H KulkeLaura E MacConaillAzra H LigonEwa SicinskaMatthew L MeyersonJeffrey A MeyerhardtAndrew D CherniackBrian M WolpinKimmie NgMarios GiannakisJason L HornickJames M Cleary
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
RTK fusions in colorectal cancer are a rare, but important disease subgroup that occurs in RAS and BRAF wild-type tumors. Despite enrichment in acquired MMR-D tumors, RTK fusions also occur in MSS colorectal cancer and provide an important therapeutic target.
Keyphrases
  • wild type
  • tyrosine kinase
  • epidermal growth factor receptor
  • cancer therapy
  • randomized controlled trial
  • drug delivery
  • binding protein
  • placebo controlled